hotspot -WSS

hotspot

author：hotspot 2025-08-23 05:03:26 - browse：7

An army of wooden figures under blue and pink lighting — biotech coverage from STAT — Adobe

In an abrupt change of course from plans earlier in the month, at-home test maker Cue Health is laying off all of its employees and shutting down as of Friday, May 24.

The company, which grew to prominence during the Covid-19 pandemic as the maker of one of the only molecular at-home tests for the virus, has been teetering on the edge of insolvency for months. The shutdown, first reported by the San Diego Union-Tribune, comes just over a week after the FDA warned consumers not to use Cue’s only FDA-authorized product, a Covid-19 test kit.

Cue had previously notified 49% of its workers on May 1 that they would be laid off from the company, effective July 1. But in a WARN notice filed with California state regulators on May 20, chief human resources officer Allison Blackwell said that due to the “fluid nature of this situation,” all U.S. employees who had not already received notice of termination would be receiving one. All employees will receive their last paychecks on May 24, the notice said.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： FDA approves first new drug developed for postpartum depression

hotspot

leisure time

WSS

Tennessee law changes starting July 1 will restrict trans health care and fund more school safety

Science's Marcia McNutt, trailblazer for women, encounters sexism scandal

Biogen nominates mother of director’s child to replace him on board

Living organ donors deserve priority status for transplants

FDA approves updated Covid vaccines

Xenotransplantation trials will require adjusting expectations, experts say

focus

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

explore

BioMarin wins approval for gene therapy to treat hemophilia A

Food makers to regulators: Ultra

FDA approval of Sarepta Duchenne genetic therapy gives me hope

FDA proposes changes to key medical devices approval pathway

The cancer drug shortage isn’t new — and neither are the solutions

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

As demand for Covid shots wanes, Moderna seeks its next success

Biden administration plans revamp of organ transplant system

BioMarin wins approval for gene therapy to treat hemophilia A

Reanimated hearts work just as well for transplants, study finds

hotspot

Sea level rise could wash away turtle breeding grounds around the world, researchers say

FDA approves updated Covid vaccines

Telehealth for opioid use disorder is lifesaving

Private equity could exacerbate cardiology's overuse problem, experts fear

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

What to make of Biden’s latest efforts on cancer research

hotspot

leisure time

Wikipedia

focus